PT-141 vs Trazodone
FDA Approved vs FDA Approved
monitor Mechanism-based · 60% Both PT-141 and Trazodone can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
PT-141 Trazodone
Weight — 371.86 Da
Half-life ~2.7 hours ~5-9 hours
Type Melanocortin receptor agonist Triazolopyridine derivative (C19H22ClN5O)
Key Benefits
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Trazodone
01 Effective sleep aid that improves sleep onset and sleep maintenance without the dependence risk of benzodiazepines
02 Enhances slow-wave (deep) sleep, which is critical for physical recovery and growth hormone release
03 Non-habit-forming with no significant tolerance development, even with long-term use
04 Widely used and well-tolerated solution for trenbolone-induced and steroid-related insomnia
05 Does not suppress REM sleep the way many other sleep medications do
06 Inexpensive, widely available as a generic, and has decades of safety data
Dosing Protocols
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Trazodone
25-100 mg at bedtime (sleep) / Once daily at bedtime
Side Effects
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Trazodone
Morning drowsiness or grogginess (dose-dependent, more common above 50 mg)
Dry mouth
Dizziness or lightheadedness, particularly upon standing (orthostatic hypotension)
Headache
Nausea (reduced by taking with food)
Blurred vision
Contraindications
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Known hypersensitivity to trazodone
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
History of priapism or conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia)
Severe hepatic impairment (dose adjustment required in moderate impairment)
Recent myocardial infarction or unstable cardiac conditions
Pregnancy, particularly first trimester (Category C; limited human data)
Research Evidence
PT-141 Trazodone
Status FDA Approved FDA Approved
References 4 studies 4 studies
Latest 2022 —
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.